Sinovac Life Sciences Co., Ltd.

This early-stage study tested a new oral rotavirus vaccine in 100 healthy people aged 6 weeks to 59 years. The main goal was to see if the vaccine is safe and well-tolerated, especially in infants. Researchers also checked how well the vaccine triggers an immune response. The tri…

This early-stage trial tested a new 24-valent pneumococcal conjugate vaccine in 119 healthy children aged 2 to 17. The goal was to see if the vaccine is safe and triggers a strong immune response against 24 types of pneumococcal bacteria. Participants received the vaccine and wer…

This study tested a new vaccine (PCV24) designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia and other infections. 385 healthy adults aged 18 and older received either the new vaccine or a control. Researchers checked for side effects and measu…

This early-stage trial tested a new 13-valent pneumococcal conjugate vaccine in 310 healthy people aged 6 weeks and older. The goal was to check the vaccine's safety and how well it triggers an immune response. Results will help decide if larger studies are needed to confirm prot…